For the past few weeks Idenix has been methodically moving away from its once-promising hepatitis C drugs, put on clinical hold by a jittery FDA in the wake of a catastrophic trial of a somewhat similar drug at Bristol-Myers Squibb.
Idenix, which had hoped to answer regulators' safety queries about IDX184 and IDX19368 and move on, says the FDA wants more time to study the drugs and the implications of the BMS-094 disaster before it makes a decision on the future of the two drugs.
Idenix Pharmaceuticals went into free fall this morning, tumbling about 40% on the news that its nucleotide polymerase inhibitor IDX184 was put on partial clinical hold as the FDA studies whether a recent cardiac event that may well have spiked a similar treatment at Bristol-Myers Squibb raises similar toxicity issues for Idenix.
Idenix and Novartis have agreed to terminate the pharma giant's option rights outlined in a 9-year-old licensing pact. Under a revised agreement, Novartis--which owns 31% of Idenix--will gain a royalty stream on approved hep C drug that comes out of the biotech.
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis
Just as regulators decided to change a full clinical hold on Idenix's lead hepatitis C drug to a partial hold, paving the way to a combo drug trial later this year, the FDA slapped a new clinical
Idenix--one of the biotech industry's star stock performers this year--saw its share price crash and burn this morning after it announced that the FDA had put its two lead hepatitis C programs on